Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia

Cecil Reuben Ross, Sitalakshmi Subramanian, Jordi Navarro-Puerto, Kannan Subramanian, Nijalingappa K. Kalappanavar, Claudia Djambas Khayat, Suchitra S. Acharya, Flora Peyvandi, Karen Rucker, Wei Liang, David Vilardell, Sabile Trimm, Jaume Ayguasanosa

Research output: Contribution to journalArticlepeer-review


Background and aims: Congenital afibrinogenemia is a rare coagulation disorder resulting from a deficiency in fibrinogen. This study assessed the pharmacokinetics, surrogate efficacy and safety of FIB Grifols, a new human plasma-derived fibrinogen concentrate, to treat congenital afibrinogenemia. Methods: Eleven adult patients from a multinational, phase 1–2, prospective, open-label, single-arm, uncontrolled clinical study received a single infusion of FIB Grifols, 70 mg/kg bw. Fibrinogen pharmacokinetics (fibrinogen activity: Clauss method; antigen plasma concentrations: ELISA) and efficacy parameters were determined over 14 days after infusion. Efficacy endpoints were the mean change on plasma maximum clot firmness (MCF) on viscoelastic testing and coagulation tests 1-hour post-infusion, and correlation with fibrinogen levels throughout. Safety parameters were also assessed. Results: For the Clauss method, (mean [standard deviation]) baseline adjusted Cmax was 1.99 (0.40) g/L, reached 1.76 (1.00) h after infusion, and half-life was 76.94 (20.21) h. Using ELISA, Cmax after FIB Grifols infusion was 2.88 (0.86) mg/mL, with a tmax of 3.06 (2.24) h. Fibrinogen activity and antigen concentrations showed statistically significant correlation of 0.9120 (P < 0.001). Surrogate efficacy was demonstrated by a significant increase of 12.35 (3.85) mm in MCF. Prothrombin time, activated partial thromboplastin time and thrombin time, returned to normal ranges over time, indicating restoration of functionally active fibrinogen. There were no treatment-related adverse events, allergic reactions, serious adverse events, or discontinuations. Conclusions: The pharmacokinetic profile of functionally active FIB Grifols was established, hemostasis was restored, and FIB Grifols was safe and well tolerated in fibrinogen-deficient patients.

Original languageEnglish
Pages (from-to)110-118
Number of pages9
JournalThrombosis Research
Publication statusPublished - Mar 2021


  • Afibrinogenemia
  • Blood coagulation factor
  • Fibrinogen
  • Hemostasis
  • Pharmacokinetics

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia'. Together they form a unique fingerprint.

Cite this